Evidence map›Paper›PMID 41642169›Full record

ArticleInternational journal of radiation oncology, biology, physics2026

Multi-institutional Normal Tissue Complication Probability (NTCP) Prediction Model for Mandibular Osteoradionecrosis: Results from the PREDMORN Study.

Laia Humbert-Vidan, Christian R Hansen, Steven Petit, Carles Muñoz-Montplet, Katrina Hueniken, Abdallah S R Mohamed, Deborah P Saunders, Vinod Patel, Gerda M Verduijn, Wilma D Heemsbergen and 22 more

Abstract readMulticenter Study
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Laia Humbert-VidanDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Medical Physics, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom. Electronic address: laia.humbert-vidan@kcl.ac.uk.
Christian R HansenDepartment of Oncology, Odense University Hospital, Odense, Denmark.
Steven PetitDepartment of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Carles Muñoz-MontpletDepartment of Medical Physics and Radiation Protection, Catalan Institute of Oncology, Girona, Spain; Department of Medical Sciences, University of Girona, Girona, Spain.
Katrina HuenikenDepartment of Biostatistics, University Health Network, Toronto, Ontario, Canada.
Abdallah S R MohamedDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, Baylor College of Medicine, Houston, Texas.
Deborah P SaundersDepartment of Dental Oncology, Health Sciences North, Northern Ontario School of Medicine University, Ontario, Ontario, Canada.
Vinod PatelDepartment of Oral Surgery, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Gerda M VerduijnDepartment of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Wilma D HeemsbergenDepartment of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Arjen van der SchaafDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Max WitjesDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Suzanne P M de VetteDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Mohammad MoharramiFaculty of Dentistry, University of Toronto, Toronto, Ontario, Canada; Department of Dental Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Abdul A KhanDepartment of Oral and Maxillofacial Surgery, Odense University Hospital, Odense, Denmark.
Jordi Marruecos QuerolDepartment of Medical Sciences, University of Girona, Girona, Spain; Department of Radiation Oncology, Catalan Institute of Oncology, Girona, Spain.
Irene Oliveras CancioDepartment of Radiation Oncology, Catalan Institute of Oncology, Girona, Spain.
Mike OliverDepartment of Medical Physics, Health Sciences North, Sudbury, Ontario, Canada.
Peter ReichHealth Sciences North Research Institute, Sudbury, Ontario, Canada.
Stacey A SantiHealth Sciences North Research Institute, Sudbury, Ontario, Canada.
Andrew G PearceDepartment of Radiation Oncology, Northern Ontario School of Medicine, Sudbury, Ontario, Canada.
Stephen Y LaiDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Andrew P KingSchool of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom.
Ali HosniDepartment of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Andrew J HopeDepartment of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Erin E WatsonFaculty of Dentistry, University of Toronto, Toronto, Ontario, Canada; Department of Dental Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Johannes A LangendijkDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Jørgen JohansenDepartment of Oncology, Odense University Hospital, Odense, Denmark.
Amy C MorenoDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Clifton D FullerDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lisanne V van DijkDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Teresa Guerrero UrbanoSchool of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom; Department of Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Targeting the p53 pathway for reversal of oral premalignancyP50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MILLS, GORDON B. · 2002 to 2012
$26.1M
Project 3: OPC-RADP01CA285249 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI STEPHEN Y LAI · 2024 to 2026
$9.4M
Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Establish Objective Clinical Outcome Measures for Mandibular OsteoradionecrosisR01DE025248 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LAI, STEPHEN Y · 2016 to 2020
$2.9M
Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-Enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI)U01DE032168 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Clifton David Fuller, STEPHEN Y LAI · 2023 to 2026
$2.8M
Ontology-based aPplications of mUlti-discipLinary knowlEdge on orodeNtal Conditions and outcomEs (OPULENCE)R01DE034406 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Amy Catherine Moreno · 2025 to 2026
$1.5M
SMART-ACT: Spatial Methodologic Approaches for Risk Assessment and Therapeutic Adaptation in Cancer TreatmentR01CA214825 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CANAHUATE, GUADALUPE, FULLER, CLIFTON DAVID · 2017 to 2019
$1.1M
imaging Radiation-Associated Dysphagia (iRAD)R01CA218148 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FULLER, CLIFTON DAVID, HUTCHESON, KATHERINE ARNOLD · 2017 to 2019
$810k
QuBBD: Precision E –Radiomics for Dynamic Big Head & Neck Cancer Data R01CA225190 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CANAHUATE, GUADALUPE, FULLER, CLIFTON DAVID · 2017 to 2019
$776k
Fellow and Resident Radiation Oncology iNtensive Training in Imaging and Informatics to Empower Research Careers (FRONTI2ER)R25EB025787 · NIBIB · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAS, PRAJNAN, FULLER, CLIFTON DAVID · 2018 to 2022
$535k
Provider and Patient-generated Remote Oro-Dental Health Electronic Data Capture for Algorithmic Longitudinal Evaluation and Risk-Assessment (PROHEALER)K01DE030524 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MORENO, AMY CATHERINE · 2022 to 2024
$479k
Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Establish Objective Clinical Outcome Measures for Mandibular OsteoradionecrosisR56DE025248 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LAI, STEPHEN Y · 2015 to 2015
$470k
NCI NIH HHS P01 CA285249NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA097007NCI NIH HHS R01 CA214825NCI NIH HHS R01 CA218148NCI NIH HHS R01 CA225190NIBIB NIH HHS R25 EB025787NIDCR NIH HHS K01 DE030524NIDCR NIH HHS R01 DE025248NIDCR NIH HHS R01 DE034406NIDCR NIH HHS R21 DE031082NIDCR NIH HHS R56 DE025248NIDCR NIH HHS U01 DE032168
6 · The paper itself

Abstract

purposeMandibular osteoradionecrosis (ORN) is a severe late complication affecting patients with head and neck cancer (HNC) treated with radiation therapy (RT) that significantly impacts patients' quality of life and can require costly interventions. Although radiation dose is a key factor, other clinical and demographic risk factors also influence ORN development. Previous predictive models have primarily been single-institutional, limiting their generalizability. In this first analysis from the PREDMORN Consortium, we have aimed to reproduce existing statistical association and modeling analyses on the largest and most diverse mandibular ORN cohort worldwide to allow comparison with previous studies. METHODS AND MATERIALS: This retrospective multi-institutional study included 3928 patients with HNC (622 ORN cases) from 8 institutions. Clinical, demographic, and dosimetric variables were analyzed to develop a prediction model (any grade ORN vs no ORN) using forward stepwise logistic regression with correlation-based variable preselection. The ORN normal tissue complication probability (NTCP) model was developed on 80% of data from 6 institutions, tested on the remaining unseen 20%, and externally validated on a matched cohort (58 patients, 19 ORN cases) and a large population-based cohort (2687 patients, 215 ORN cases).

resultsKey predictors of ORN were D

conclusionsThe PREDMORN NTCP model is the largest multi-institutional effort to date aimed at predicting ORN risk in patients with HNC using real-world data. The model demonstrated good generalizability when externally validated to a large population-based cohort. Our observations align with current guidelines and corroborate findings from smaller single-institution studies.

Indexed as

Head and Neck NeoplasmsMandibular DiseasesModels, StatisticalOrgans at RiskOsteoradionecrosisAgedFemaleHumansLogistic ModelsMaleMandibleMiddle AgedProbabilityRadiotherapy DosageRetrospective StudiesRisk Factors

Identifiers

PMID41642169
PMCPMC12930408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.